Invitation to presentation of Ascelia Pharma’s Q4 report 2018/2019

Ascelia Pharma’s full-year report for the period July 2018 – June 2019 (FY 2018/2019) will be published on Thursday 22 August 2019 at 09:00 CET. A presentation for analysts, media and investors will be held the same day at 09:00 CET.

The event will be hosted by the company’s CEO Magnus Corfitzen, CFO Kristian Borbos and CMO Carl Bjartmar. The presentation will be held in English. 

The presentation can be followed live via the link:
https://tv.streamfabriken.com/ascelia-pharma-q4-2018-2019
 

It will also be possible to take part of the audiocast afterwards at the same address or at Ascelia Pharma’s website.

To participate in the telephone conference, please use the dial-in details shown below:
SE: +46 85 055 83 50

UK: +44 33 3300 9267

US: +1 833 823 0587

For more information, please contact:

Magnus Corfitzen, CEO
Email: moc@ascelia.com
Tel.
46 735 179 110

Mikael Widell, IR & Communications Manager
Email: mw@ascelia.com
Tel: +46 703 11 99 60

The information was submitted for publication, through the agency of the contact person set out above, at 7:45 a.m. CET on 20 August 2019.

About Ascelia Pharma
Ascelia Pharma is an oncology-dedicated orphan drug development company located in Malmö, Sweden. The company’s strategy is to develop drugs, which target unmet medical needs, have an established mode of action and a relatively low development risk. Ascelia Pharma has two drug candidates – Mangoral® and Oncoral – currently under development.

Mangoral is a novel contrast agent for MR-scans and is ready for Phase III clinical studies. Mangoral is developed to improve the visualization of focal liver lesions (liver metastases) in patient with impaired kidneys that cannot tolerate current gadolinium contrast agents on the market. Oncoral is an oral chemotherapy tablet ready for Phase II for the treatment of gastric cancer. Ascelia Pharma is listed on Nasdaq Stockholm (ticker: ACE). For more information, please visit www.ascelia.com.

Tags:

About Us

Ascelia Pharma is an oncology-dedicated orphan drug development company located in Malmö, Sweden. The company’s strategy is to develop drugs, which target unmet medical needs, have an established mode of action and a relatively low development risk. Ascelia Pharma has two drug candidates – Mangoral® and Oncoral – currently under development. Mangoral is a novel contrast agent for MR-scans and is ready for Phase III clinical studies. Mangoral is developed to improve the visualisation of focal liver lesions (liver metastases) in patient with impaired kidneys that cannot tolerate current gadolinium contrast agents on the market. Oncoral is an oral chemotherapy tablet ready for Phase II for the treatment of gastric cancer. Ascelia Pharma is listed on Nasdaq Stockholm (ticker: ACE). For more information, please visit www.ascelia.com

Subscribe

Quick facts

Ascelia Pharma is an oncology-dedicated orphan drug development company located in Malmö, Sweden. The company’s strategy is to develop drugs, which target unmet medical needs, have an established mode of action and a relatively low development risk. Ascelia Pharma has two drug candidates – Mangoral® and Oncoral – currently under development. Mangoral is a novel contrast agent for MR-scans and is ready for Phase III clinical studies. Mangoral is developed to improve the visualization of focal liver lesions (liver metastases) in patient with impaired kidneys that cannot tolerate current gadolinium contrast agents on the market. Oncoral is an oral chemotherapy tablet ready for Phase II for the treatment of gastric cancer. Ascelia Pharma is listed on Nasdaq Stockholm (ticker: ACE). For more information, please visit www.ascelia.com
Tweet this